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Abstract
In this study, we performed a survey of infantile and late-onset Pompe disease (IOPD and LOPD) in Austria. Paediatric and 
neuromuscular centres were contacted to provide a set of anonymized clinical and genetic data of patients with IOPD and 
LOPD. The number of patients receiving enzyme replacement therapy (ERT) was obtained from the pharmaceutical com-
pany providing alglucosidase alfa. We found 25 patients in 24 families, 4 IOPD and 21 LOPD with a resulting prevalence 
of 1:350,914. The most frequent clinical manifestation in LOPD was a lower limb-girdle phenotype combined with axial 
weakness. Three patients were clinically pauci- or asymptomatic and were diagnosed because of persistent hyperCKemia. 
Diagnostic delay in LOPD was 7.4 ± 9.7 years. The most common mutation was c.-32-13T > G. All IOPD and 17 symp-
tomatic LOPD patients are receiving ERT. Standardized follow-up was only available in six LOPD patients for the 6-min 
walk test (6minWT) and in ten for the forced vital capacity (FVC). Mean FVC did not decline (before ERT; 63.6 ± 39.7%; 
last evaluation during ERT: 61.9 ± 26.9%; P = 0.5) while there was a trend to decline in the mean distance covered by the 
6minWT (before ERT: 373.5 ± 117.9 m; last evaluation during ERT: 308.5 ± 120.8 m; P = 0.077). The study shows a lower 
prevalence of Pompe disease in Austria than in other European countries and corroborates a limb-girdle phenotype with 
axial weakness as the most common clinical presentation, although asymptomatic hyperCKemia may be the first indication 
of LOPD.
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Introduction
Pompe disease, also known as glycogenosis type 2 or 
acid maltase deficiency, is an autosomal recessive disease 
caused by > 450 mutations in the GAA gene (http://clus-
ter15.erasmusmc.nl/klgn/pompe/mutations.html) which 
lead to deficiency of the lysosomal enzyme acid alpha-
glucosidase [1]. Depending on residual enzyme activity 
symptoms may develop during the first months of life 
(infantile-onset Pompe disease, IOPD) or during child-
hood, adolescence or adulthood (late-onset Pompe disease, 
LOPD) [2]. Untreated IOPD causes rapidly progressive 
muscle weakness and cardiomyopathy which usually is 
fatal within 1–2 years [3]. LOPD generally takes a milder 
course with slowly progressive muscle weakness without 
cardiomyopathy. However, overtime many patients need 
ventilatory support due to respiratory weakness [1].
Pompe disease is a rare disorder with an estimated 
prevalence of 1:283,000 in Europe [4]. However, it is 
assumed that the prevalence is higher as several studies in 
patients with unexplained myopathies detected new cases 
with undiagnosed LOPD [5, 6]. Since enzyme replace-
ment therapy (ERT) has become the standard treatment for 
Pompe disease [7], increased efforts have been undertaken 
to further delineate the phenotype of Pompe disease to 
allow early diagnosis and treatment.
The efficacy of ERT is impressive in most IOPD patients, 
improving cardiac, respiratory and motor function as well as 
overall survival [8]. In LOPD, the effect of ERT, although 
significant in a RCT and also shown in a large meta-analysis 
[7, 9], is less pronounced. The high costs and the limited 
effects of treatment resulted in guidelines offering criteria 
when to start and when to stop treatment in some countries 
[10] and recently European guidelines were formulated [11].
To expand clinical, genetic and epidemiologic data on 
this rare disease and to provide results on the effects of ERT, 
we report the Austrian cohort of IOPD and LOPD patients.
Methods
This retrospective observational study was approved by 
the ethics committee of the Medical University, Innsbruck. 
Austrian neuromuscular and paediatric centres were con-
tacted and asked whether they currently manage or treat 
patients with IOPD or LOPD. To cross-check, we also 
contacted the pharmaceutical company providing ERT 
(Sanofi-Genzyme) to inquire about the number of Austrian 
patients receiving alglucosidase alfa  (Myozyme®).
Centres were asked to provide a set of anonymized clin-
ical and genetic data of their patients: age; gender; age at 
symptom onset; age at diagnosis; genetic results; biochem-
ical data; EMG results; age when ERT was started; dis-
tribution of muscle weakness, respiratory function, 6-min 
walk test (6minWT) before ETR and at last visit; in IOPD 
cardiac function and CRIM (cross-reactive immunological 
material) status.
Genetic test results were compared with the Pompe muta-
tions database (http://cluster15.erasmusmc.nl/klgn/pompe/
mutations.html) and mutations in the GAA gene are reported 
based on reference sequence NM_000152.3. Results are 
given as mean ± SD (range).
Results
25 patients with Pompe disease from 24 families, 4 with 
IOPD and 21 with LOPD, were detected. The calculated 
prevalence of Pompe disease in Austria is 1:350,914 (popu-
lation of 8,772,865; http://www.statistik-oesterreich.at/web_
de/klassifikationen/regionale_gliederungen/bundeslaender/
index.html).
IOPD
In these four patients (three female) first symptoms devel-
oped at the age of 2, 2, 9 and 10 months. Diagnosis of 
Pompe disease was made at 3, 6, 12 and 18 months, respec-
tively. All displayed motor developmental delay and gener-
alized weakness. The two younger children had the classi-
cal presentation with cardiomyopathy (CMP). All patients 
had normal cognitive function on formal evaluation. Only 
one patient underwent MRI of the brain which was normal. 
Evoked potentials and nerve conduction studies have not 
been performed.
All patients were found to be CRIM positive and ERT 
was initiated immediately after diagnosis. At present, these 
patients have been receiving ERT for 8.75, 9.5 and 11 years, 
without developing antibodies against rhGAA (Genzyme 
Clinical Specialty Lab, One Mountain Road, Framing-
ham, MA). ERT was just recently started in the boy (c.-
32-13T > G/deletion exon 18).
ERT improved CMP in both children with classical 
early-onset disease. The later (at 6 months) diagnosed girl 
(c.784G > A/c.1057delC, new mutation) had never been 
able to walk and showed dramatic deterioration of her 
muscular phenotype following a severe pulmonary infec-
tion at age 8 years. At present, she has a tracheostoma and 
needs ventilatory support for almost 24 h/day. The other girl 
(c.1195-2A > G/c.1195-2A > G) with symptom onset at age 
2 months and immediate start of ERT is ambulatory and 
without ventilation. The girl with disease onset at 9 months 
without CMP (c.-32-13T > G/c.1050-1051delGG) is fully 
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ambulatory but requires non-invasive ventilation during 
nighttime.
LOPD
Selected individual clinical findings are shown in Table 1.
Two male pts (ID 19, 20) and one female pt (ID 21) were 
investigated because of pauci- or asymptomatic hyperCK-
emia (726 and 1447 U/l) at the age of 15, 11 and 13 years, 
respectively. Symptom onset in the other 18 LOPD patients 
(9 f/9 m) was 24.9 ± 13.9 years (range: 3.5–47 years). At 
the initial evaluation, limb-girdle weakness was found in 
17 patients; 15 of these also had axial weakness, 8 also had 
respiratory weakness and only 4 scapular winging. Isolated 
respiratory weakness was observed in only one case. Weak-
ness was found in the proximal lower limbs in 17 cases, 
while the upper limbs were affected in only eight.
CK was elevated in all but one symptomatic pt; 
990 ± 684 U/l (118–2437). EMG studies were available 
from 15 pts and fibrillations/positive sharp waves were 
documented in six cases, myotonic discharges in only two. 
MRI was performed in only four patients; a hypoplastic 
vertebral artery was found in two, while the MRI was 
normal in the others. All LOPD patients were compound 
heterozygous and the common Caucasian mutation c.-
32-13T > G was found in 17 cases, new mutations in four 
(http://cluster15.erasmusmc.nl/klgn/pompe/mutations.
html).
Diagnostic delay in the non-familial cases (n = 19) was 
7.4 ± 9.7 years (range: 0.5–34 years). All but the pauci- 
or asymptomatic patients and one symptomatic patient, 
who declined treatment, are currently receiving ERT. 
Treatment was started just recently in two patients; the 
other 15 pts have been treated for 7.8 ± 3.5 years (range: 
1–12 years). Treatment was well tolerated without side 
effects. Anti-rhGAA antibodies were tested in 7 pts and 
were positive in only one with a very low titre of 1:1600.
The effect of ERT on 6minWT and FVC could be evalu-
ated in only 6 and 10 pts, respectively (Fig. 1a, b). Mean 
FVC did not decline (before ERT: 63.6 ± 39.7%; last eval-
uation during ERT: 61.9 ± 26.9%; P = 0.5) while there 
was a trend towards a decline in the mean distance covered 
by the 6minWT (before ERT: 373.5 ± 117.9 m; last evalu-
ation during ERT: 308.5 ± 120.8 m; P = 0.077).
Table 1  Demographic, clinical and genetic data of the Austrian LOPD patients
New mutations are bold
nk not known, l limb-girdle weakness, a axial weakness, r respiratory weakness, s scapula alata, HyperCK asymptomatic hyperCKemia, ERT 
enzyme replacement therapy
* pt. decided to stop treatment after 2 years due to lack of efficacy and severe disease, ** ERT recently started
ID Gender Age Symptom onset 
[years]
Findings at 
presentation
Diagnostic 
delay [years]
Duration of 
ERT [years]
Genetics allel 1 Genetics allel 2
1 M 36 21 l, a 6 8 c.-32-13T > G c.877G > A
2 F 65 44 l, a, r 10 11 c.-32-13T > G c.1912G > T
3 F 26 18 l, a, r 1 7 c.-32-13T > G c.2281delinsAT
4 F 58 25 l, a, r 18 8 c.-32-13T > G c.307T > G
4a M 56 46 r 0 6 c.-32-13T > G c.307T > G
6 F 37 22 l, a, r 1 8 c.-32-13T > G c.1076-2G > A
7 M 27 11 l, a 5 11 c.692 + 5G > T c.953T > C
8 F 29 18 l 0.5 11 c.-32-13T > G c.877G > A
9 M 38 21 l, a, r, s 0.5 11 c.-32-13T > G c.1051delG
10 F 64 47 l 3 12 c.-32-13T > G c.271G > A
11 M 62 24 l, a, s 34 3 c.-32-13T > G c.1051delG
12 F 50 nk l, a, r nk  8 c.-32-13T > G c.271delG
13 M 39 nk l, a, r nk  * c.-32-13T > G c.955 + 2T > G
14 M 37 28 l, a, s 8 1 c.-32-13T > G c.271 G > A
15 M 16 3.5 l, a 1.5 11 c.1076-22T > G c.525delT
16 M 13 6 l, a, s 6.5 1 c.1548G > A c.1470C > A
17 F 69 40 l, a, r 28 ** c.-32-13T > G c.323G > C
18 F 25 nk l, a nk ** c.-32-13T > G c.2608C > T
19 M 15 15 HyperCK 0.5 0 c.-32-13T > G c.2380dupC
20 M 11 8 HyperCK 3 0 c.-32-13T > G c.2051C > G
21 W 13 12.5 HyperCK 0.5 0 c.1134C > G c.1478C > T
162 Journal of Neurology (2018) 265:159–164
1 3
Discussion
The prevalence of Pompe disease in Austria found in the 
present study, 1:350,914, is considerably lower than that 
reported for Europe, 1:283,000 [4]. Although the prevalence 
of Pompe disease varies [2] it is reasonable to assume that 
there are still some undiagnosed individuals with Pompe 
disease in Austria. In the paediatric cohort, children with 
the severe, classical course of IOPD are generally less prone 
to be missed due to the rapidly progressive, life-threatening 
course. In contrast, late-onset patients with slowly progres-
sive myopathy but without cardiac involvement experience 
not only a significant diagnostic delay but the diagnosis may 
also be missed.
The frequency of undiagnosed LOPD has been investi-
gated in several studies [6, 12–17] and in the largest of these 
studies, 2.4% of patients with hyperCKemia or limb-girdle 
muscular dystrophy (LGMD) of unknown origin were found 
to have LOPD [6]. This suggests that there are also some 
undiagnosed LOPD patients in Austria, and is supported 
by pts 19, 20 and 21, who were diagnosed by whole exome 
sequencing for diagnostic workup of pauci- or asymptomatic 
hyperCKemia.
The clinical symptoms of the Austrian LOPD cohort are 
in line with the typical findings in Pompe disease [18–20]. 
Core features are proximal lower limb and axial weakness, 
frequently in combination with respiratory weakness, while 
scapular winging is rare. Although such a pattern of weak-
ness is also seen in LGMD, especially prominent axial and 
respiratory weakness should alert the clinician to search for 
Pompe disease. Despite these suggestive clinical features, 
mean diagnostic delay was 8.8 years, which is similar to 
previous reports [18–21]. Several factors have been found 
to influence the diagnostic delay, such as presenting signs 
and symptoms, year of diagnosis and age at symptom onset 
[18–21]. Due to the small sample size, these factors can-
not be statistically analysed in our population, but it seems 
that age is an important factor as the mean diagnostic delay 
was 18.6 years in patients currently older than 40 years and 
only 2.8 years in patients younger than 40 years. As Pompe 
disease is a progressive disorder, which causes significant 
morbidity and increased mortality [7], early diagnosis and 
treatment are essential [22]. It remains to be seen whether 
simplified diagnostic procedures such as the dried blood spot 
test [23], easily accessible genetic testing and campaigns to 
increase awareness will further reduce the diagnostic delay 
in the near future.
Besides typical clinical findings, electromyographic 
(EMG) abnormalities, in particular spontaneous activity 
and myotonic discharges, have been considered to be suspi-
cious for Pompe disease [24]. Results from EMG studies 
were available in only 15 of our patients and myotonic dis-
charges and abnormal spontaneous activity were observed 
in only two and six patients, respectively. Only a few stud-
ies reported the frequency of these EMG abnormalities in 
Pompe disease, and some found them frequently [25, 26] 
others only rarely [27, 28] in their population. This discrep-
ancy might be explained by the muscles studied as Kassard-
jian et al. [26] clearly showed that the highest diagnostic 
yield can be achieved when sampling from paraspinal mus-
cles and the tensor fasciae latae muscles. This might also 
explain the low rate of EMG abnormalities in our cohort as 
these muscles have not been investigated.
The c.-32-13T > G mutation was the most frequent muta-
tion (85%) found in Austrian LOPD patients, which equals 
reports from nearby European countries [19, 27–30]. Similar 
to other studies, we also found some new mutations, which 
were all predicted to be pathological and Pompe disease 
has been verified by reduced enzyme activity either in the 
dried blood spot test or in muscle tissue. In contrast, the c.-
32-13T > G mutation was only seen in 50% of IOPD. The 
known mutations found in IOPD are predicted to be severe 
with the exception of c.784G > A, which is predicted to be 
potentially less severe (http://cluster15.erasmusmc.nl/klgn/
pompe/mutations.html). In this case the second, yet unde-
scribed frameshift mutation c.1057delC, p.(Gln353Serfs*39) 
probably defines the rather severe phenotype.
The response to ERT could be evaluated in only about 
half of the patients who underwent yearly standardized 
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Fig. 1  Effects of enzyme replacement therapy (ERT) on a FVC 
(n = 10) and b 6-min walk test (6minWT, n = 6)
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assessments. Recently published European guidelines [11] 
recommend a standardized regular monitoring to gain more 
knowledge about the disease course under ERT to facilitate 
informed, cost-sensitive treatment decisions. As can be seen 
from the figures, the effects of ERT vary between patients 
and as nicely described by [22] there are obvious responders 
and non-responders. In the patients we were able to analyse, 
the 6minWT improved or remained unchanged in only two 
of six, while FVC improved or remained unchanged in seven 
of ten. This is somewhat different to treatment responses 
reported in a large meta-analysis [7]. However, a compari-
son between the published results and those presented here 
seems invalid, as our population is small and the observation 
periods vary greatly.
To summarize, in this study we report the phenotypes 
and genotypes of Austrian IOPD and LOPD patients and 
their response to treatment. The genotype corresponds to 
that described in other European countries and the reported 
clinical features corroborate the typical phenotype in LOPD 
with limb-girdle and axial weakness in the majority of 
patients. The incidence in Austria, however, is lower than 
that reported for Europe, suggesting that some patients go 
undiagnosed. Despite the fact that all patients have access 
to ERT, the recommended yearly standardized assessment 
is only performed in about half.
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